Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01948024 · ClinicalTrials.gov registry record · Phase 1
Bio-equivalence Study Between SAPHRIS and Asenapine
A Phase 1 study, sponsored by Sun Pharmaceutical Industries Limited.
- Completed
- Registry status
- Phase 1
- Development phase
- 65
- Enrollment target
NCT01948024 is a Phase 1 study that has completed, run by Sun Pharmaceutical Industries Limited. The registered enrollment target is 65 participants.
The verdict
NCT01948024, a Phase 1 study, has completed, sponsored by Sun Pharmaceutical Industries Limited.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 65 participants
- Enrollment target
Study Summary
This is a Multiple-dose, steady state, three-way reference-replicated crossover study. The purpose of this Study is to determine the bio-equivalence between SAPHRIS and Asenapine 10mg sublingual tablets.
Interventions
- DRUG SAPHRIS
- DRUG Asenapine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 65 participants |
| Start Date | 2013-07 |
| Est. Completion | 2013-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01948024
The ClinicalTrials.gov registry entry for NCT01948024 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 65 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sun Pharmaceutical Industries Limited, which has 38 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which SAPHRIS is the first listed.
NCT01948024 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01948024 about?
NCT01948024 is a clinical study titled "Bio-equivalence Study Between SAPHRIS and Asenapine". This is a Multiple-dose, steady state, three-way reference-replicated crossover study. The purpose of this Study is to determine the bio-equivalence between SAPHRIS and Asenapine 10mg sublingual tablets.
What is the current status of trial NCT01948024?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 65 participants. The study started on 2013-07. Estimated completion is 2013-08.
What interventions are being tested in trial NCT01948024?
The interventions under investigation include: SAPHRIS (DRUG), Asenapine (DRUG).
Who is sponsoring clinical trial NCT01948024?
This trial is sponsored by Sun Pharmaceutical Industries Limited, which has 38 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.